Biotech Daily

Monday June 2, 2025

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH DOWN: IMPEDIMED UP 10%; CLARITY DOWN 12%**

*** MAY BDI-40 DOWN 2.6%, ASX200 UP 3.8%, BIG CAPS UP 2.3%, NBI DOWN 4.2%**

*** VICTORIA, LA TROBE UNI A.I. MEDICAL RESEARCH SUPER-COMPUTER**

*** INOVIQ: OVARIAN CANCER TEST '77% SENSITIVITY, 99.6% SPECIFICITY'**

*** CARDIEX TGA CONNEQT PULSE APPROVAL**

*** RADIOPHARM: RV01 PRE-CLINICAL 'BIODISTRIBUTION, TUMOR UPTAKE'**

*** LUMOS RECRUITS 50% OF FEBRIDX BARDA STUDY**

*** TRUSCREEN 'COMMITMENTS' FOR $2.2m PLACEMENT**

*** NEUROTECH 'POSITIVE' NTI164 MARIJUANA PHARMACO-KINETICS**

*** RENERVE, BERKLEY BIOLOGICS TO SELL 2 NERVE REPAIR PRODUCTS**

*** IMUGENE OPENS 1st AUSTRALIAN PHASE II PD-1 VAXX SITE**

*** MAYNE FILES THERAPEUTICS MD US LEGAL COMPLAINT**

*** DR BILL GARNER DILUTED TO 14% OF ISLAND**

*** OPTHEA LOSES 4 OF 8 DIRECTORS**

*** IMAGION AGM 45% OPPOSE 7.5m CPS CAPITAL OPTIONS**

MARKET REPORT

The Australian stock market fell 0.24 percent on Monday June 2, 2025, with the ASX200 down 20.6 points to 8,414.1 points. Nine of the Biotech Daily Top 40 companies were up, 28 fell, two traded unchanged and one was untraded. The four Big Caps were mixed.

Impedimed was the best, up 0.3 cents or 10 percent to 3.3 cents, with 10.5 million shares traded. Curvebeam and Starpharma climbed five percent or more; Medical Developments was up 3.1 percent; Orthocell and Prescient rose more than two percent; Genetic Signatures and Medadvisor were up one percent or more; with Cochlear, CSL and Nanosonics up by less than one percent.

Clarity the falls, down 26.5 cents or 12.3 percent to $1.895, with 5.8 million shares traded. Botanix and Cynata lost more than eight percent; 4D Medical was down 7.35 percent; Mesoblast shed 6.2 percent; Aroa and Compumedics were down more than five percent; Actinogen and Clinuvel fell more than four percent; Atomo, Avita, Emvision, Nova Eye, Optiscan, Paradigm, Polynovo and Syntara were down three percent or more; Dimerix, EBR, Neuren, Proteomics and Universal Biosensors shed more than two percent; Alcidion, Cyclopharm, Immutep, Micro-X and SDI were down more than one percent; with Pro Medicus, Resmed and Telix down by less than one percent.

BIOTECH DAILY TOP 40 INDEX (BDI-40)

The May Biotech Daily Top 40 Index (BDI-40) fell 2.6 percent to a collective market capitalization of $20,583 million, the four Big Caps of Cochlear, CSL, Pro Medicus and Resmed (which are not included in the BDI-40) were up 2.3 percent to $222,372 million and the benchmark ASX200 rose 3.8 percent to 8,434.7 points.

Pro Medicus again led the Big Caps, up $5,094 million or 21.3 percent to $29,059 million, Resmed rose 3.3 percent to $55,571 million, Cochlear fell 1.7 percent to $17,657 million, with CSL down 1.2 percent to $120,085 million.

The BDI-40 was basically even, with 18 companies up, nine by more than 10 percent; and 19 companies down, with nine down by more than 10 percent.

Medadvisor was the best, recovering $30 million or 52.6 percent to $87 million, followed by Dimerix, up $66 million or 24.5 percent to $335 million, Neuren (20.3%), Syntara (19.8%), Nova Eye (19.4%), Genetic Signatures (18.5%), Proteomics (17.6%) Aroa (15.8%) and Paradigm (12.6%).

Again, the deepest market capitalization falls were greater than the percentage falls; with Telix shedding $555 million, but just 6.1 percent of its market capitalization followed by Mesoblast losing $166 million or 7.2 percent and Nanosonics falling $121 million or 8.3 percent.

Avita led the percentage falls, down $164 million (40.0%) to $246 million, followed by Imugene (37.4%), Universal Biosensors (23.5%), Orthocell (22.3%), Actinogen (22.1%), Impedimed (20.8%), Botanix (16.4%), Curvebeam (16.2%) and Emvision (13.7%).

Comparing the raw numbers from the previous year, the BDI-40 fell 32.95 percent over the 12 months, but at this time last year, Pro Medicus was worth $12,538 million and has been promoted into the Big Caps. Comparing the 40 companies with themselves, the BDI-40 was up 9.7 percent for the year to May 31, 2025, compared to the ASX200 up 9.5 percent and the four Big Caps up 3.85 percent.

The 11 companies in Cannabis Corner climbed a collective 3.2 percent in May to $226 million, down 14.4 percent for the 12 months to May 31, 2025. Three were up, six fell and two were unchanged. Bioxyne was the best, up 35.6 percent to $61 million, with Inhalerx and Zelira looking good with 20 percent increases, but that was a rise from $5 million to $6 million. Argent (MGC) was the worst, down $2 million or 22.2 percent to $7 million.

Outside the BDI-40, Adalta fell to $1 million; while Alterity improved 37.0 percent, Artrya climbed 21.1 percent and Imricor was at its year's $558 million high.

In the US, the Nasdaq Biotechnology Index (NBI) fell 4.2 percent in May to 4,079 points – down 7.3 percent for the 12 months. Eyepoint (Psivida) climbed $42 million or 5.7 percent to $775 million, while Incannex climbed 300 percent to $24 million after last month's 80 percent tumble from $30 million to $6 million - for no reason we could discern, and no response from the company. Queensland's Protagonist was up 4.3 percent to $4,574 million, with both Kazia and Neuphoria (Bionomics) up 33.3 percent to $8 million and $36 million, respectively.

BDI-40 v ASX200 Jun 30, 2006 to May 31, 2025- Adjusted



Big Caps $m (COH, CSL, PME, RMD) May 31, 2020 – May 31, 2025



BDI-40 ($m) v S&P ASX 200 – Jan 31, 2020 – May 31, 2025 (Pre-Covid to date)



VICTORIA GOVERNMENT, LA TROBE UNIVERSITY

The Victoria Government says the first artificial intelligence (A.I.) Nvidia DGX H200 super-computer in Australia is undertaking medical research in Melbourne.

Last year, the Victoria Government said it invested $10 million to help La Trobe University build its Australian Centre for Artificial Intelligence in Medical Innovation, or Acami, for researchers using A.I. to advance medical research (BD: Sep 13, 2024).

Today, a media release from Victoria's Minister for Economic Growth and Jobs Danny Pearson said the super-computer had been installed at Next DC's Melbourne Data Centre in Tullamarine and would be used to "accelerate research into clinical trials and treatments to improve health outcomes for patients".

The Government said the super-computer had "the ability to process complex [three-dimensional] imaging and analyze huge amounts of health data in just hours, making it faster and easier to improve diagnoses".

The Victoria Government said the technology would help "accelerate innovations that span from precision oncology and immuno-therapy to cardiovascular risk prediction, digital pathology and breast and colorectal cancer relapse-risk prediction".

The Government said Acami was based at La Trobe University and would bring together "world-leading experts in A.I. and medical research to change the way we diagnose and treat cancer, infectious and cardiovascular diseases".

A separate media release from La Trobe University said it would partner with multiple organizations through Acami to collaborate on drug discovery and medical innovation.

The University said one of the first projects to use the systems would be the Florey Institute of Neuroscience and Mental Health's research on the progressive neuro-degenerative disorder Niemann-Pick disease type C in children.

La Trobe University said Next DC's Tullamarine site was "one of the few operations in the Southern Hemisphere which has A.I.-ready infrastructure available to connect the A.I. super-computer to high density power and innovative cooling … designed for high performance computing".

The University said it would initially commission three Nvidia DGX H200 systems.

La Trobe University said the A.I. industry was "expected to create 200,000 jobs in Australia by 2030".

The Victoria Government said it was supporting Victoria's medical research institutes "with more than $24 million invested in the Victorian Budget 2025-'26 so they can continue generating lifesaving treatments and supporting jobs".

The Government said health technologies and medical research were "identified as top priority areas in the economic growth statement".

Mr Pearson said Victoria was "proud to be home to this super-computer that will deliver more medical breakthroughs and improve the healthcare for Victorians and people around the world".

"There are now three world-leading centres of medical research, Boston, London and Victoria, and this ground-breaking technology will support our world-leading researchers to accelerate medical innovations in the state," Mr Pearson said.

La Trobe vice-chancellor Prof Theo Farrell said that artificial intelligence was "revolutionizing society at great speed and La Trobe is committed to ensuring that our students and the communities we serve are empowered to adapt and succeed in this rapidly changing world".

Prof Farrell said the University's Acami provided "a hands-on training ground for Australian scientists, clinicians and data scientists, building sovereign A.I. expertise that is crucial for rural and Indigenous health initiatives, biotech competitiveness and the nation's long-term digital health resilience."

INOVIQ

Inoviq says a 532-sample study showed its EXO-OC exosome-based ovarian cancer blood test has 77 percent sensitivity and 99.6 percent specificity for all stages of disease.
Inoviq said the results were presented in a poster, titled 'Early detection of ovarian cancer: An accurate high-throughput extracellular vesicle test', at the American Society of Clinical Oncology meeting in Chicago from May 30 to June 3, 2025.
The poster included research by Dr Robert Bast et al. published in Cancer Epidemiology, Biomarkers & Prevention saying that "due to the low incidence of ovarian cancer, clinically accepted screening guidelines require that any test used in an asymptomatic population must have a sensitivity of at least 75 percent and a specificity of at least 99.6 percent".
Inoviq said the test used an artificial intelligence (A.I.) algorithm and had "accurately detected all early-stage I and II cancers with no missed diagnoses".
The company said the test was "run on a fully-automated, high-throughput instrument suitable for clinical pathology laboratories, with capacity to process over 500 samples daily".
Inoviq said it had filed an Australian provisional patent application to protect the intellectual property related to various protein and RNA biomarker combinations and methods for the exosome ovarian cancer test.
The company said it would conduct validation studies to confirm the test's specificity for ovarian cancer compared to other cancer types and inflammatory conditions, seek breakthrough device designation and US Food and Drug Administration pre-market approval before commercialization.
Inoviq chief executive officer Dr Leearne Hinch said the company's test addressed "a critical unmet need for early detection of ovarian cancer".
"We are focused on the rapid commercialization of our test, first as a laboratory developed test and then as a regulatory approved in-vitro diagnostic for ovarian cancer screening," Dr Hinch said.
Inoviq was up 12.5 cents or 28.4 percent to 56.5 cents with 3.6 million shares traded.

CARDIEX

Cardiex says the Australian Therapeutic Goods Administration has approved the commercial sale of its Conneqt Pulse arterial heart monitor.
In 2023, Cardiex said it had US Food and Drug Administration 510(k) clearance for its Conneqt Pulse for measuring brachial and central blood pressure (BD: Apr 26, 2023).
Last month, the company said it filed an application to the TGA to include Conneqt Pulse on the Australian Register of Therapeutic Goods (BD: May 6, 2025).
Today, Cardiex said the device was "a world-first, clinical-grade, vascular biometric, monitoring device for use in both clinical and remote patient monitoring or at-home".
The company said the device allowed for the measurement "of a broad range of arterial health biomarkers, including central blood pressure and arterial stiffness, which are key indicators for cardiovascular risk and vascular health".
Cardiex said it would "begin exploring commercialization opportunities in Australia with an initial focus on pharmaceutical, research and clinician markets".
Cardiex managing-director Craig Cooper said TGA approval was "another milestone … as we expand our regulatory and commercial opportunities".
"While the US remains our primary focus at this stage, we're excited to begin laying the foundation for growth in Australia," Mr Cooper said.
Cardiex was up 0.1 cents or 2.3 percent to 4.5 cents.

RADIOPHARM THERANOSTICS

Radiopharm says pre-clinical data for its lutetium-177 B7H3-monoclonal antibody RV01 shows “favorable biodistribution and … maintained tumor uptake.”

Radiopharm said R0V1 was its B7H3-targeted radio-pharmaceutical therapy being developed with Houston’s University of Texas MD Anderson Cancer Center and was designed to target solid tumors that expressed the B7H3 protein.

In 2022, Radiopharm said it had a joint-venture with the MD Anderson Cancer Centre to develop radio-pharmaceutical products for cancer and hoped to develop at least four products based on the MD Anderson Centre’s intellectual property (BD: Sep 14, 2022).

Last year, the company said it paid MD Anderson Cancer Centre $US4 million ($A5.9 million) to increase to 75 percent ownership of its joint-venture which continued “to show promising progress in its cancer therapeutic pipeline, including the advancement of its leading B7H3 candidate and other preclinical assets” (BD: Aug 26, 2024).

At that time, Radiopharm said the B7H3 monoclonal antibody lead candidate was an immune checkpoint protein with high expression in cancer and was associated with greater tumor size and lymphatic invasion.

Today, the company said the data confirmed “conclusions from earlier pre-clinical mouse studies” and completed the pre-clinical package for an investigational new drug submission to the US Food and Drug Administration in mid-2025 with a first-in-human phase I therapeutic study expected to begin by 2026.

Radiopharm did not disclose the details of the pre-clinical study.

Radiopharm chief medical officer Dr Dimitris Voliotis said the antibody showed “faster liver excretion in the preclinical experiments, allowing the isotope enough time to effectively target the tumor potentially without the associated toxicities”.

“Unlike peptides or small molecules, [monoclonal antibodies] are excreted by the liver, the most radio-resistant organ,” Dr Voliotis said.

“This, combined with the faster excretion due to the shortened half-life, potentially offers important advantages compared to excretion via the kidneys, where the elimination of radio-pharmaceuticals can result in a significant potential toxicities,” Dr Voliotis said.

Radiopharm was up 0.4 cents or 16.7 percent to 2.8 cents with 7.4 million shares traded.

LUMOS DIAGNOSTICS

Lumos says it has enrolled 61 of 120 bacterial positive patients in a study of its Febridx blood test for differentiating bacterial and non-bacterial respiratory infections.

Last year, Lumos said it received $US2,984,571 ($A4,350,000) from the US Biomedical Advanced Research and Development Authority (BARDA); and later, said it had a $US925,217 ($A1,486,000) milestone payment from BARDA for opening its 800-patient trial of its Febridx finger-prick blood test (BD: Oct 3, Dec 20, 2024).

Today, the company said it had enrolled 439 patients to date and that testing of 500 patients would trigger a further $US298,457 milestone payment from BARDA.

Lumos said the bacterial prevalence rate in the study so far was at an average of 13.9 percent, or 61 of 439 patients, but since it “implemented its enrichment strategy in late March the bacterial prevalence rate in the trial has been around 35 percent”.

The company said the results would support a US Food and Drug Administration clinical laboratory improvement amendment (CLIA) waiver, which it hoped to submit by October 2025.

Lumos managing-director Doug Ward said reaching the halfway mark in bacterial positive patient recruitment for the study was “an important achievement for Lumos”.

Lumos was up 0.1 cents or 3.6 percent to 2.9 cents with four million shares traded.

TRUSCREEN

Truscreen says it has “firm commitments” to raise $NZ2,354,750 ($A2,187,419) in a placement at 2.2 NZ cents (2.0 Australian cents) a share.
Last week, Truscreen said it hoped to raise $NZ3.0 million through a $NZ1,780,230 placement at 2.2 NZ cents a share and a $NZ1,220,796 share plan (BD: May 29, 2025).
At that time, Biotech Daily calculated the placement price of 2.0 cents a share was a 25.9 percent discount to Truscreen’s last closing price of 2.7 cents.
Today, the company said it had received commitments “from both new and existing investors”, with the share purchase plan for shareholders on the record date of May 28 to open on June 3 and close on June 23, 2025.
Truscreen fell 0.3 cents or 11.1 percent to 2.4 cents.

NEUROTECH INTERNATIONAL

Neurotech says it has ‘positive results’ from its 12-participant, first-in-human pharmaco-kinetic study of its marijuana-based NTI164.
Last year, Neurotech said it had human research ethics committee approval to begin a pharmaco-kinetic study of NTI164 in 12 healthy adult volunteers (BD: Nov 25, 2024).
At that time, the company said the study would administer 20mg/kg of NTI164 to four participants in two doses about 12 hours apart, followed by eight participants who would be dosed with the same regimen of NTI164 for seven consecutive days.
Today, Neurotech said the study confirmed “rapid and predictable absorption of NTI164’ with ‘cannabidiolic acid’ (CBDA) as the dominant circulating cannabinoid.
The company said “CBDA reached peak plasma levels up to 3,801 nanograms per millilitre (ng/mL) within two-to-four hours, demonstrating rapid and predictable systemic absorption”.
Neurotech said tetra-hydro-cannabidiol (THC) exposure was consistently minimal at 9.5ng/mL, “even at steady-state conditions, affirming NTI164’s non-intoxicating safety profile”.
The company said “no significant cannabinoid accumulation was observed, with steady-state conditions achieved by day three and only a modest increase (about 17 percent) seen after multiple doses, indicating no accelerated build-up of cannabinoids in the body”.
Neurotech said that “twice-daily dosing provided effective 24-hour therapeutic coverage, ideal for paediatric management” and that NTI164 showed a stable CBDA to cannabidiol (CBD) plasma ratio of around 16 to 1 “indicating minimal conversion of CBDA into CBD in the body”.
The company said the results formed “a robust [pharmaco-kinetic] data package that justifies dose selection and strengthens the product's benefit-risk profile, all essential for achieving positive regulatory outcomes”.
Neurotech said the study showed NTI164 had “excellent tolerability with no systemic or organ-specific toxicities or serious adverse events, supporting NTI164's favourable safety profile for chronic paediatric administration”.
Neurotech managing-director Dr Anthony Filippis said the results were “another important clinical milestone for NTI164”.
“The clear validation of systemic stability, safety and targeted therapeutic action highlights NTI164's potential as a disease-modifying therapy,” Dr Filippis said.
“We are eager to advance NTI164 rapidly into the next stages of its development and regulatory progress, while actively pursuing commercial opportunities,” Dr Filippis said.
Neurotech was unchanged at 2.1 cents with 1.8 million shares traded.

RENERVE

Renerve says with the Richmond, California-based Berkley Biologics LLC it will develop and commercialize two complementary tissue-based nerve repair products.
Renerve said it had an initial five-year supply deal for the products, which were already approved in the US and would be produced at Berkley Biologics' facility in California.
The company said one product range addressed "the need for human dermal tissue, deeper layers of the skin often sourced from donors, and the other providing a range of amniotic tissue products, which are known for their regenerative and healing properties".
Renerve said the products addressed "multiple surgical applications including trauma and wound care, breast reconstruction, foot and ankle procedures, extremity repairs, and orthopaedic and plastic surgeries".
The company said the products allowed "surgeons to incorporate additional tissue grafts when treating nerve injuries, addressing both the damaged nerve and underlying trauma".
Renerve said the products had application in the medical procedures indicated for its Nervalign nerve repair and replacement products, and that the sale of the additional products would be an extension of its current sales activities.
The company said it expected to launch the first product by October 2025, with the second to be commercialized "before year-end".
Renerve was up half a cent or 4.8 percent to 11 cents.

IMUGENE

Imugene says it has opened its phase II trial of its PD-1-Vaxx therapy for operable colorectal cancer at Adelaide's Queen Elizabeth Hospital, the first Australian site.
In 2023, Imugene said its up-to 44-patient, phase II trial for operable colorectal cancer at six sites in Australia and four in the UK had the primary objective to determine pathological response rates by measuring pre-surgery tumor size (BD: Dec 6, 2023).
Today, the company said the investigator-sponsored trial was conducted by Cancer Research UK Southampton Clinical Trials Unit with Royal Surrey Hospital National Health Services Foundation Trust and the Australasian Gastro-Intestinal Trial Group.
Imugene managing-director Leslie Chong said the company was "very pleased to see this … [trial] open and enrolling in Australia".
"PD1-Vaxx has the potential to offer a durable immune response and improve treatment outcomes," Ms Chong said.
Imugene was unchanged at 1.5 cents with 30 million shares traded.

MAYNE PHARMA

Mayne Pharma says it has filed a complaint in the US District Court for the District of Delaware against Therapeutics MD Inc (TXMD).
Mayne Pharma said it asserted "claims against TXMD for breach of contract and fraud based on allegations that TXMD concealed information about certain commercialization assets it sold to Mayne Pharma on December 4, 2022".
Earlier this year, the company said TXMD had filed legal proceedings against one of its US subsidiaries in the US District Court for the District of Delaware (BD: Apr 11, 2025).
Today, the company said it was "seeking more than $US11.5 million ($A17.8 million) in damages it incurred as a result of TXMD's alleged misrepresentation about the assets".
Mayne said it had filed a motion to dismiss TXMD's proceeding in its entirety and "emphatically denies any and all allegations of wrongdoing".
Mayne Pharma fell two cents or 0.4 percent to $4.93 with 325,477 shares traded.

ISLAND PHARMACEUTICALS

The San Juan, Puerto Rico-based Dr Bill Garner says his 33,198,166 share-holding in Island has been diluted from 15.79 percent to 14.21 percent on May 29, 2025.
Last week, Island said it had “firm commitments” to raise $3.6 million at 15 cents a share in a placement to fund a trial of ISLA-101 (BD: May 21, 2025).
Island fell 1.5 cents or 6.7 percent to 21 cents.

OPTHEA

Opthea says following negative trial results and its reduction in work force four of its eight directors have “decided to step down from the board to streamline governance”.
Earlier this year, Opthea said its 993-patient, phase III Coast trial of OPT-302 with aflibercept for wet AMD “failed to meet [its] primary endpoint” and it might be required to pay its Development Funding Agreement (DFA) investors amounts that would have a material adverse impact on its solvency (BD: Mar 24, 2025).
Later, the company said it would discontinue its wet age-related macular degeneration (AMD) trials after its ‘Shore’ phase III trial of OPT-302 with ranibizumab missed its primary endpoint of mean change in best corrected visual acuity (BD: Mar 31, 2025).
Last month, Opthea said that “in light of the negative trial results” it would decrease costs, including reducing its workforce by about 65 percent (BD: Apr 10, 2025).
Today, the company said the directors Dr Julia Haller, Dr Susan Orr, Quinton Oswald and Anshul Thakral had resigned, effective from today.
Opthea said it remained in “active negotiations with its Development Funding Agreement (DFA) investors, pursuant to and as required under the DFA, to explore possible options to deliver the best outcome for the company and its shareholders”.
Opthea chair Dr Jeremy Levin said he “would like to wholeheartedly thank the departing directors for their contribution to Opthea over many years and their dedication to progressing the science in ophthalmology”.
“I am grateful for Ms Kathy Connell, Mr Lawrence Gozlan and Mr Sujal Shah who will continue to serve moving forward with me,” Dr Levin said.
Opthea was in a suspension and last traded at 60 cents.

IMAGION BIOSYSTEMS

Imagion says its annual general meeting passed all resolutions with up-to 44.67 percent against the ratification of the issue of 7,500,000 options to CPS Capital Group.
Last month, Imagion said investors would vote to issue 2,000,000 options to executive chair Robert Proulx and non-executive director Brett Mitchell, each, as well as the ratification of shares to Market Bull and options to CPS Capital (BD: May 1, 2025).
Today, the company said the approval of the 10 percent placement capacity was opposed by 1,594,981 votes (11.23%), with 11,971,838 votes (88.77%) in favor.
Imagion said Mr Proulx and Mr Mitchell’s options were opposed by 17.5 percent of the meeting, with the ratification of options to CPS Capital opposed by 1,045,012 votes (44.67%) and shares to Market Bull facing 1,020,768 votes (43.14%) opposition.
The company said the re-election of Mr Mitchell as a director and the remuneration report were passed more easily with more than 88.83 percent support.
According to its most recent filing, Imagion had 201,341,415 shares on issue, meaning that the 1,594,981 votes against the placement capacity amounted to 0.8 percent of the company, not sufficient to requisition extraordinary general meetings.
Imagion fell 0.05 cents or four percent to 1.2 cents.

BIOTECH DAILY TOP 40 WITH MARKET CAPITALIZATION AT MAY 31, 2025

Company $Am	May 31, 2024	Apr 30, 2025	May 31, 2025
Cochlear	20,953	17,957	17,657
CSL	134,499	121,600	120,085
Pro Medicus	12,538	23,965	29,059
Resmed	46,129	53,800	55,571
BDI-20			
Avita	386	410	246
Clarity	1,580	707	694
Clinuvel	759	569	547
Compumedics	43	59	57
Cyclopharm	155	130	133
Cynata	60	44	41
EBR Systems	339	455	476
Genetic Signatures	136	92	109
Immutep	535	394	416
Impedimed	154	77	61
Medical Developments	37	68	73
Mesoblast	1,267	2,294	2,128
Nanosonics	824	1,457	1,336
Neuren	2,646	1,470	1,769
Nova Eye	56	31	37
Orthocell	76	386	300
Polynovo	1,519	836	902
SDI	94	100	101
Syntara	24	91	109
Telix	5,259	9,167	8,612
Second 20			
4D Medical	231	144	158
Actinogen	73	86	67
Alcidion	78	115	115
Amplia	19	19	19
Aroa	196	152	176
Atomo	19	12	11
Botanix	457	879	735
Curvebeam	58	37	31
Dimerix	272	269	335
Emvision	161	168	145
Imugene	490	179	112
Medadvisor	242	57	87
Micro-X	53	39	37
Optiscan	96	113	117
Paradigm	87	111	125
Prescient	36	37	37
Proteomics	127	51	60
Resonance	29	19	20
Starpharma	47	39	36
Universal Biosensors	43	17	13

* Biotech Daily editor, David Langsam, owns shares in 4D Medical, Acrux, Actinogen, Alcidion, Alterity, Amplia, BTC Health, Clarity, Cochlear, Control Bionics, Cynata, EBR, Nanosonics, Neuren, Patrys, Polynovo, Syntara and Telix as well as non-biotech stocks. Through Australian Ethical Superannuation he has an indirect interest in other companies: **https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/**. These holdings are liable to change.

Biotech Daily can be contacted at: PO Box 500, Flemington, Victoria, Australia, 3031
email: editor@biotechdaily.com.au; www.biotechdaily.com.au